DOAC in Chinese Patients With Atrial Fibrillation

Sponsor
Chinese University of Hong Kong
Study ID
NCT05378035
Status
Recruiting
Apply to this trial

Conditions

  • Arterial Thromboembolism
  • Atrial Fibrillation
  • Brain Diseases
  • Major Adverse Cardiovascular Event
  • Stroke
  • Stroke, Acute
  • Venous Thromboembolism

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Blood Tests — DIAGNOSTIC_TEST
    Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.

Study Details

Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, and rivaroxaban - were shown to reduce the risk of major bleeding compared to warfarin. The predictable pharmacokinetic profiles of DOACs also favour their use over warfarin. Together with increasing AF incidence due to population ageing, increased AF detection, and territory-wide reimbursement schemes, DOAC prescriptions have been surging worldwide. In Hong Kong, more than 78,354 patients received DOAC from January 2009 through April 2021 according to the Hospital Authority registry. The more liberal use of DOACs has led to new issues that require a thorough understanding of ethnic-specific DOAC pharmacokinetic profiles. For instance, 12- 15% of anticoagulated patients annually required interventional procedures that involve temporary discontinuation of DOAC for 48 hours or more. Although guideline-based periprocedural DOAC interruption resulted in a low 30-day thromboembolism rate of 0.16% - 0.6% in a Caucasian cohort, same measures for elective colonoscopies in a local population-based study resulted in a 30-day periprocedural thromboembolism rate of up to 2.2%. Although these studies cannot be compared directly, the remarkable interethnic discrepancy between the two cohorts warrants further pharmacokinetic and pharmacogenomic studies. More importantly, quantifying residual DOAC levels during the interruption periods may imply on duration of periprocedural DOAC interruption, length of hospital-stay, and the risk of thromboembolic and bleeding complications. Mapping inter- and intra-individual variations in DOAC levels may also impact on the management of ischemic stroke among DOAC recipients. Epidemiological studies have shown alarmingly up to 13% of acute ischemic stroke patients were on anticoagulation prior to stroke onset with increasing number of DOAC. These patients received low rates of recanalization therapy due to apprehension of bleeding complications, thus compromised survival and neurological recovery. A prospective study that reveals Asian-specific DOAC pharmacokinetic profiles may inform cross-disciplinary, territory-wide periprocedural care and acute stroke intervention strategy for the rapidly expanding DOAC population.

Key Dates

First listed
May 17, 2022
Start date
Sep 28, 2022
Status verified
Jan 2025
Primary completion
Sep 27, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
427 participants (estimated)

Arms

  • Arm: DOAC Recipients
    We shall recruit the DOAC recipients that meet the following inclusion criteria: 1. Chinese NVAF patients on apixaban, dabigatran, edoxaban, or rivaroxaban for 6 months or more. 2. Patients aged 18-80 years old. 3. Patients who are able to provide an informed consent. 4. Patients who are indicated for elective medical procedures that require interruption of DOAC for 48 hours, such as colonoscopy, pleural biopsy, cardiac catheterization, digital subtraction angiograph, etc.

Primary Outcome Measure

Specific coagulation assays [ Time Frame: December, 2024 ]

Central Contacts

Find similar trials

Nationwide
Atrial fibrillation trialsStroke trialsCardiology trialsHeart disease trialsNeurology trialsBrain disorders trials

Related Studies